Acceleron Pharma Inc. (NASDAQ:XLRN) SVP Ravindra Kumar sold 13,065 shares of the company’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $35.41, for a total transaction of $462,631.65. Following the sale, the senior vice president now directly owns 108,392 shares in the company, valued at $3,838,160.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Ravindra Kumar also recently made the following trade(s):
- On Wednesday, July 5th, Ravindra Kumar sold 937 shares of Acceleron Pharma stock. The shares were sold at an average price of $32.00, for a total transaction of $29,984.00.
Shares of Acceleron Pharma Inc. (XLRN) opened at 34.10 on Friday. The stock’s 50 day moving average price is $32.33 and its 200 day moving average price is $28.88. The company’s market capitalization is $1.32 billion. Acceleron Pharma Inc. has a 12 month low of $23.07 and a 12 month high of $41.69.
Acceleron Pharma (NASDAQ:XLRN) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.65) by $0.12. Acceleron Pharma had a negative return on equity of 44.67% and a negative net margin of 724.22%. The business had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $3.69 million. During the same period in the prior year, the firm posted ($0.59) earnings per share. The firm’s revenue for the quarter was down 3.1% on a year-over-year basis. On average, analysts forecast that Acceleron Pharma Inc. will post ($2.73) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Insider Selling: Acceleron Pharma Inc. (XLRN) SVP Sells 13,065 Shares of Stock” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/08/12/insider-selling-acceleron-pharma-inc-xlrn-svp-sells-13065-shares-of-stock.html.
Hedge funds and other institutional investors have recently bought and sold shares of the company. BNP Paribas Arbitrage SA boosted its position in Acceleron Pharma by 969.9% in the second quarter. BNP Paribas Arbitrage SA now owns 3,627 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 3,288 shares in the last quarter. NJ State Employees Deferred Compensation Plan acquired a new position in Acceleron Pharma during the second quarter worth approximately $213,000. Bank of Montreal Can acquired a new position in Acceleron Pharma during the first quarter worth approximately $237,000. Parametric Portfolio Associates LLC acquired a new position in Acceleron Pharma during the first quarter worth approximately $241,000. Finally, Tudor Investment Corp ET AL boosted its position in Acceleron Pharma by 8.5% in the first quarter. Tudor Investment Corp ET AL now owns 9,105 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 716 shares in the last quarter. 83.65% of the stock is currently owned by institutional investors.
Several equities research analysts have commented on XLRN shares. Credit Suisse Group reaffirmed an “outperform” rating and set a $46.00 price objective on shares of Acceleron Pharma in a report on Tuesday, April 18th. JMP Securities reaffirmed an “outperform” rating and set a $39.00 price objective on shares of Acceleron Pharma in a report on Monday, May 1st. Zacks Investment Research downgraded shares of Acceleron Pharma from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. Goldman Sachs Group, Inc. (The) started coverage on shares of Acceleron Pharma in a report on Wednesday, May 17th. They set a “sell” rating and a $20.00 price objective on the stock. Finally, FBR & Co reaffirmed a “buy” rating on shares of Acceleron Pharma in a report on Thursday, May 18th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $41.53.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
What are top analysts saying about Acceleron Pharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Acceleron Pharma Inc. and related companies.